Adocia announces its financial calendar for 2022
ADOCIA SA, a French société anonyme (corporation), 115, avenue
Lacassagne, 69003 Lyon, (Euronext Paris: FR0011184241 – ADOC) a
clinical stage biopharmaceutical company focused on diabetes
treatments and other metabolic diseases with innovative
formulations of peptides and proteins, announced today its
financial calendar for 2022.
February 23, 2022:
Publication of revenue for Q4 2021.
April 19, 2022:
Publication of 2021 financial statements.
May 18, 2022:
Publication of revenue for Q1 2022.
August 24, 2022:
Publication of revenue for Q2 2022.
September 19, 2022:
Publication of mid-year financial statements as of June 30,
October 25, 2022:
Publication of revenue for Q3 2022.
In addition to regular meetings with the
financial community, investors can also find updated information on
the company’s website (www.adocia.com). All corporate information
on the company such as its financial statements, its corporate
presentation and its status is available on the company’s website,
in the Investors’ section, « Regulated Information ».
Adocia is a clinical-stage biotechnology company
that specializes in the development of innovative formulations of
therapeutic peptides and proteins for the treatment of diabetes and
metabolic diseases. In the diabetes field, Adocia’s portfolio of
injectable treatments is among the largest and most differentiated
of the industry, featuring six clinical-stage products and several
Adocia’s clinical pipeline includes five novel
insulin formulations for the treatment of diabetes: two ultra-rapid
formulations of insulin analog lispro (BioChaperone® Lispro U100
and U200), a combination of basal insulin glargine and rapid acting
insulin lispro (BioChaperone® Combo) and two combinations of a
prandial insulin with amylin analog pramlintide (M1Pram and
BioChaperone® LisPram). The clinical pipeline also includes an
aqueous formulation of human glucagon (BioChaperone® Glucagon) for
the treatment of hypoglycemia.
Adocia’s preclinical pipeline includes
bi-hormonal combinations for diabetes treatment: a combination of
aspart rapid acting insulin analog and pramlintide (BioChaperone®
AsPram), a combination of insulin glargine with GLP-1 receptor
agonist (BioChaperone® Glargine Liraglutide). In addition, there
are three multi-hormonal products for the treatment of obesity: a
combination of glucagon and exenatide (BioChaperone® GluExe), a
combination of pramlintide and exenatide (PramExe) and a triple
combination of pramlintide glucagon exenatide (BioChaperone®
Adocia's portfolio is based on three technology
platforms: 1) The BioChaperone® platform is designed to enhance the
effectiveness and/or safety of therapeutic proteins while making
them easier for patients to use; 2) A platform designed to improve
cell therapy techniques using a hydrogel matrix; 3) A platform for
the oral delivery of peptides.
SoulaCEOcontactinvestisseurs@adocia.com Ph: +33 4 72
MC Services AGAdocia Press Relations Europe Raimund
Gabriel, Shaun Brown, Andreas
Jungferadocia@mc-services.euPh: +49 89 210 228 0
This press release contains certain forward-looking statements
concerning Adocia and its business. Such forward-looking statements
are based on assumptions that Adocia considers as being reasonable.
However, there can be no guarantee that the estimates contained in
such forward-looking statements will be achieved, as such estimates
are subject to numerous risks including those which are set forth
in the “Risk Factors” section of the universal registration
document that was filed with the French Autorité des marchés
financiers on April 20, 2021 (a copy of which is available at
www.adocia.com), in particular uncertainties that are linked to
research and development, future clinical data, analyses, and the
evolution of the economic context, the financial markets and
the markets in which Adocia operates. The forward-looking
statements contained in this press release are also subject to
risks not yet known to Adocia or not considered as material by
Adocia as of this day. The occurrence of all or part of such risks
could cause that actual results, financial conditions,
performances, or achievements of Adocia be materially different
from those mentioned in the forward-looking statements. This press
release and the information contained herein do not constitute an
offer to sell or the solicitation of an offer to buy Adocia’s
shares in any jurisdiction.
から 11 2022 まで 12 2022
から 12 2021 まで 12 2022